Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.

× No keyword cloud information.

15 in total

1. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors: Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal: J Pharmacokinet Pharmacodyn Date: 2005-08 Impact factor: 2.745

Review 2. Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors: J M Cedarbaum
Journal: Clin Pharmacokinet Date: 1987-09 Impact factor: 6.447

3. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans.

Authors: R Surtees; K Hyland
Journal: J Neurol Neurosurg Psychiatry Date: 1990-07 Impact factor: 10.154

4. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.

Authors: M J Heeringa; F d'Agostini; P DeBoer; M DaPrada; G Damsma
Journal: J Neural Transm (Vienna) Date: 1997 Impact factor: 3.575

5. The role of 3-O-methyldopa in the side effects of L-dopa.

Authors: Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal: Neurochem Res Date: 2007-08-24 Impact factor: 3.996

6. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Authors: Dag Nyholm; Per Odin; Anders Johansson; Krai Chatamra; Charles Locke; Sandeep Dutta; Ahmed A Othman
Journal: AAPS J Date: 2012-12-11 Impact factor: 4.009

3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.

1. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Review 2. Clinical pharmacokinetics of anti-parkinsonian drugs.

3. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans.

4. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.

5. The role of 3-O-methyldopa in the side effects of L-dopa.

6. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

7. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.

8. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

9. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.

10. Methyl conjugation in uraemia: catechol-O-methyltransferase.